

First Patient Enrolled Major e-health Respiratory Management Clinical Study

Highlights:

- First patient now enrolled in landmark study to examine the benefit of e-health systems to improve patient outcomes and lower health care costs.
- Study has included purchase order for 4,000 Hailie® sensors, to support 2,500 patients.
- Positive data from this trial will potentially seed expansion and further program implementation across Intermountain's 300,000 patients.

Melbourne, Australia – 20 March 2024: Leading digital health company Adherium Limited (ASX:ADR) is pleased to announce the first patient has been enrolled in a newly cemented research partnership between US Intermountain Health and CareCentra using Hailie® sensors to monitor key physiological data.

The focus of the collaboration between Adherium, CareCentra and Intermountain Health is to conduct a large scale real-world chronic respiratory disease clinical study, to examine and demonstrate the benefit of embedding e-health systems to improve patient outcomes and lower health care costs.

Study preparations included a purchase order for 4,000 Hailie® sensors. The iCare study will involve 2,500 patients across five Intermountain facilities over two years to transform respiratory management for chronic obstructive pulmonary disease (COPD) and asthma patients.

The study leverages Intermountain's network of respiratory clinics, physicians and hospitals; CareCentra's leading behavioural science and AI capabilities; and Adherium's Hailie remote sensor technology – all aimed at providing a clinical assessment of the health and economic benefits of e-health management of chronic respiratory disease.

The study will use Adherium's next generation Hailie sensors to provide real-time, remote data to the CareCentra AI which continuously monitors patient risk levels with a complex algorithm of data points, including signals of when and how patients are using prescribed inhaler medication from the Hailie device. These data points provided by Adherium's Hailie remote sensor technology allow the CareCentra platform to assess health risk, recommend behavioral shifts in technique or adherence, and if problems persist, alert Intermountain Health for timely interventions and tailored treatments to improve health outcomes. These efforts can greatly reduce adverse events and hospital admissions.

Hailie sensors accurately monitor peak inspiratory flow, inspiratory flow duration, inhaled volume and other metrics ensuring a patient's prescribed medication

effectively reaches their lungs. Hailie® is the only US FDA 510(k) cleared, drug-agnostic digital sensor providing physiological data insights on inhaler technique.

Adherium CEO, Dr. Paul Mastoridis, said: *"This is a groundbreaking partnership that accelerates the trajectory of Adherium both clinically and financially in line with our recent pivot to full commercialisation in the US through large scale strategic partnerships."*

"The iCARE study will provide further clinical validation of Hailie's next generation sensors and measure behavioural shifts and healthcare cost reductions, to validate how Hailie enables a new value-based e-healthcare model that benefits everyone from patients and doctors to hospitals and insurers."

Intermountain Health Associate Medical Director for Pulmonary and Respiratory Care, Peter Crossno, M.D., Ph.D., said: *"Patients can struggle with their COPD and asthma and medication adherence more than we know. The iCare model, integrating Adherium data within the CareCentra AI platform and user-friendly app, can be an early warning system and provide immediate feedback and trends to patients and their carers on adherence, inhaler technique, triggers and more."*

CareCentra's behavior shaping platform and AI uses a range of data points, including expiratory flow rate, respiratory rate, oxygen saturation, heart rate, inspiratory flow rate, and date/time stamps of medication adherence to monitor rising health risk and nudge both patient and respiratory care teams to control exacerbations and improve outcomes. The iCare study's goal is to leverage cutting edge digital health technology and respiratory biomarkers to identify rising risks and engage patients and providers in co-managing that risk, improving outcomes and reducing healthcare costs.

CareCentra CEO, Vasant Kumar, said: *"Intermountain Health and CareCentra have a long-standing relationship developing healthcare innovation, research and technology to fundamentally redesign how patients manage chronic and acute conditions. The CareCentra AI remotely monitors, triages and alerts care teams for just-in-time intervention, to help prevent hospitalisation in a range of chronic and acute conditions. The iCare study is an important validation of this approach in COPD and asthma practice and at scale."*

- ENDS -

Learn more at adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.



ASX Release

Investor Enquiries

Dr. Paul Mastoridis
Adherium Limited
Chief Executive Officer
investors@adherium.com

Media Enquiries:

Haley Chartres
H^CK
Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at adherium.com